


2008

CURRENT

Medical Diagnosis & Treatment



STEPHEN J. MCPHEE | MAXINE A. PAPADAKIS

Senior Editor

LAWRENCE M. TIERNEY, JR.

Mc
Graw
Hill

LANGUE

LANGE
2008
CURRENT
Medical Diagnosis
& Treatment

FORTY-SEVENTH EDITION

Edited by

Stephen J. McPhee, MD

Professor of Medicine
Division of General Internal Medicine
Department of Medicine
University of California, San Francisco

Maxine A. Papadakis, MD

Professor of Clinical Medicine
Associate Dean for Student Affairs
School of Medicine
University of California, San Francisco

Senior Editor

Lawrence M. Tierney, Jr., MD

Professor of Medicine
University of California, San Francisco
Associate Chief of Medical Service
Veterans Affairs Medical Center, San Francisco

With Associate Authors



New York Chicago San Francisco Lisbon London Madrid Mexico City
Milan New Delhi San Juan Seoul Singapore Sydney Toronto

Contents

Authors	xi	5. Palliative Care & Pain Management	67
Preface	xvii	<i>Michael W. Rabow, MD, & Steven Z. Pantilat, MD</i>	
1. Disease Prevention & Health Promotion	1	Definition & Scope of Palliative Care	67
<i>Michael Pignone, MD, MPH, & Stephen J. McPhee, MD</i>		Pain Management	67
Prevention of Infectious Diseases	1	Principles of Pain Management	67
Prevention of Cardiovascular Disease	4	Pharmacologic Pain Management Strategies	68
Prevention of Physical Inactivity	10	Nonpharmacologic Treatment	76
Prevention of Overweight & Obesity	12	Pain at the End of Life	76
Cancer Prevention	13	Palliation of Other Common Symptoms	77
Prevention of Injuries & Violence	15	Dyspnea	77
Substance Abuse: Alcohol & Illicit Drugs	16	Nausea & Vomiting	77
		Constipation	78
		Delirium & Agitation	78
		End-of-Life Care	78
2. Common Symptoms	19	6. Dermatologic Disorders	85
<i>Ralph Gonzales, MD, MSPH</i>		<i>Timothy G. Berger, MD</i>	
Cough	19	Principles of Dermatologic Therapy	85
Dyspnea	21	Common Dermatoses	90
Chest Pain	23	Pigmented Lesions	90
Hemoptysis	25	Scaling Disorders	92
Fever & Hyperthermia	28	Vesicular Dermatoses	104
Involuntary Weight Loss	30	Weeping or Crusted Lesions	108
Fatigue & Chronic Fatigue Syndrome	31	Pustular Disorders	110
Acute Headache	33	Erythemas	116
Dysuria	35	Blistering Diseases	120
		Papules	121
3. Preoperative Evaluation & Perioperative Management	38	Violaceous to Purple Papules & Nodules	124
<i>Joshua S. Adler, MD, & Hugo Q. Cheng, MD</i>		Pruritus (Itching)	126
Evaluation of the Asymptomatic Patient	38	Inflammatory Nodules	129
Cardiac Risk Assessment	38	Epidermal Inclusion Cysts	131
Pulmonary Evaluation in Non-Lung Resection Surgery	42	Photodermatitis	132
Evaluation of the Patient with Liver Disease	43	Ulcers	133
Preoperative Hematologic Evaluation	44	Miscellaneous Dermatologic Disorders	134
Neurologic Evaluation	45	Pigmentary Disorders	134
Management of Endocrine Diseases	46	Baldness (Alopecia)	135
Renal Disease	48	Nail Disorders	136
Antibiotic Prophylaxis of Surgical Site Infections	48	Dermatitis Medicamentosa (Drug Eruption)	137
4. Geriatric Disorders	51	7. Disorders of the Eyes & Lids	141
<i>C. Bree Johnston, MD, MPH, G. Michael Harper, MD, & C. Seth Landefeld, MD</i>		<i>Paul Riordan-Eva, FRCS, FRCOphth</i>	
Assessment of Older Adults	51	Refractive Errors	141
Management of Common Geriatric Problems	56	Disorders of the Lids & Lacrimal Apparatus	142
Dementia	56	Conjunctivitis	143
Depression	59	Pinguecula & Pterygium	145
Delirium	59	Corneal Ulcer	146
Immobility	60	Acute Angle-Closure Glaucoma	147
Falls & Gait Disorders	61	Chronic Glaucoma	148
Urinary Incontinence	62	Uveitis	149
Weight Loss & Malnutrition	64	Cataract	150
Pressure Ulcers	64	Retinal Detachment	151
Pharmacotherapy & Polypharmacy	65	Vitreous Hemorrhage	152
		Age-Related Macular Degeneration	152
		Central & Branch Retinal Vein Occlusions	153
		Central & Branch Retinal Artery Occlusions	154

Amaurosis Fugax	154	Myocarditis & the Cardiomyopathies	351
Retinal Disorders Associated with Systemic Diseases	155	Acute Rheumatic Fever & Rheumatic Heart Disease	358
AIDS	156	Diseases of the Pericardium	360
Ischemic Optic Neuropathy	157	Pulmonary Hypertension & Pulmonary Heart Disease	363
Optic Neuritis	157	Neoplastic Diseases of the Heart	365
Optic Disk Swelling	158	Cardiac Involvement in Miscellaneous Systemic Diseases	366
Ocular Motor Palsies	158	Traumatic Heart Disease	367
Dysthyroid Eye Disease	159	The Cardiac Patient & Pregnancy	367
Orbital Cellulitis	159	Cardiovascular Screening of Athletes	368
Ocular Trauma	159		
Ultraviolet Keratitis (Actinic Keratitis)	161		
Treatment of Ocular Disorders	161		
Precautions in Management of Ocular Disorders	161		
Adverse Ocular Effects of Systemic Drugs	167		
8. Ear, Nose, & Throat	168	11. Systemic Hypertension	370
<i>Joshua Schindler, MD, Lawrence Lustig, MD, Robert K. Jackler, MD, & Michael J. Kaplan, MD</i>		<i>Michael Sutters MD, MRCP(UK)</i>	
Diseases of the Ear	168	Approach to Hypertension	371
Diseases of the Nose & Paranasal Sinuses	181	Drug Therapy: Current Antihypertensive Agents	381
Diseases of the Oral Cavity & Pharynx	189	Resistant Hypertension	394
Diseases of the Salivary Glands	194	Hypertensive Urgencies & Emergencies	394
Diseases of the Larynx	195		
Tracheostomy & Cricothyrotomy	200		
Foreign Bodies in the Upper Aerodigestive Tract	200		
Diseases Presenting as Neck Masses	201		
9. Pulmonary Disorders	203	12. Blood Vessels & Lymphatics	398
<i>Mark S. Chesnutt, MD, James A. Murray, DO, & Thomas J. Prendergast, MD</i>		<i>Joseph H. Rapp, MD, Rajabrata Sarkar, MD, PhD, & Catherine K. Chang, MD</i>	
Common Manifestations of Lung Disease	203	Atherosclerotic Peripheral Vascular Disease	398
Dyspnea	203	Nonatherosclerotic Vascular Disease	404
Cough	204	Arterial Aneurysms	405
Disorders of the Airways	204	Venous Diseases	409
Pulmonary Infections	225	Diseases of the Lymphatic Channels	416
Pulmonary Neoplasms	242	Shock	418
Interstitial Lung Disease (Diffuse Parenchymal Lung Disease)	244		
Disorders of the Pulmonary Circulation	249		
Environmental & Occupational Lung Disorders	261		
Pleural Diseases	267		
Disorders of Control of Ventilation	272		
Acute Respiratory Failure	274		
Acute Respiratory Distress Syndrome	277		
10. Heart Disease	280	13. Blood Disorders	422
<i>Thomas M. Bashore, MD, Christopher B. Granger, MD, & Patrick Hranitzky, MD</i>		<i>Charles A. Linker, MD</i>	
Congenital Heart Disease	280	Anemias	422
Valvular Heart Disease	287	Neutropenia	438
Coronary Heart Disease (Atherosclerotic CAD, Ischemic Heart Disease)	300	Leukemias & Other Myeloproliferative Disorders	439
Disturbances of Rate & Rhythm	325	Lymphomas	451
Bradycardias & Conduction Disturbances	337	Disorders of Hemostasis	456
Congestive Heart Failure	341	Hypercoagulable States	468
		Blood Transfusions	470
		14. Gastrointestinal Disorders	473
		<i>Kenneth R. McQuaid, MD</i>	
		Symptoms & Signs of Gastrointestinal Disease	473
		Diseases of the Peritoneum	494
		Diseases of the Esophagus	499
		Diseases of the Stomach & Duodenum	514
		Diseases of the Small Intestine	528
		Diseases of the Colon & Rectum	539
		Anorectal Diseases	561
		15. Liver, Biliary Tract, & Pancreas	566
		<i>Lawrence S. Friedman, MD</i>	
		Jaundice (Icterus)	566
		Diseases of the Liver	569
		Diseases of the Biliary Tract	597
		Diseases of the Pancreas	604

16. Breast 610*Armando E. Giuliano, MD*

Benign Breast Disorders	610
Fibrocystic Condition	610
Fibroadenoma of the Breast	611
Nipple Discharge	611
Fat Necrosis	612
Breast Abscess	612
Disorders of the Augmented Breast	613
Carcinoma of the Female Breast	613
Carcinoma of the Male Breast	632

17. Gynecology 634*H. Trent MacKay, MD, MPH*

Abnormal Premenopausal Bleeding	634
Postmenopausal Vaginal Bleeding	636
Premenstrual Syndrome (Premenstrual Tension)	636
Dysmenorrhea	637
Vaginitis	637
Cervical Polyps	639
Cyst & Abscess of Bartholin's Duct	639
Effects of Exposure to Diethylstilbestrol in Utero	639
Cervical Intraepithelial Neoplasia (Dysplasia of the Cervix)	640
Carcinoma of the Cervix	641
Leiomyoma of the Uterus (Fibroid Tumor)	643
Carcinoma of the Endometrium	644
Carcinoma of the Vulva	644
Endometriosis	645
Pelvic Organ Prolapse	646
Uterine Prolapse	647
Pelvic Inflammatory Disease (Salpingitis, Endometritis)	647
Ovarian Cancer and Ovarian Tumors	648
Polycystic Ovary Syndrome	649
Painful Intercourse (Dyspareunia)	650
Infertility	651
Contraception	653
Rape	661
Menopausal Syndrome	662

18. Obstetrics & Obstetric Disorders 665*William R. Crombleholme, MD*

Diagnosis of Pregnancy	665
Essentials of Prenatal Care	665
Nutrition in Pregnancy	668
Travel & Immunizations During Pregnancy	669
Vomiting of Pregnancy (Morning Sickness) & Hyperemesis Gravidarum (Pernicious Vomiting of Pregnancy)	669
Spontaneous Abortion	669
Recurrent (Habitual) Abortion	671
Ectopic Pregnancy	671
Preeclampsia-Eclampsia	672
Gestational Trophoblastic Disease (Hydatidiform Mole & Choriocarcinoma)	675
Third-Trimester Bleeding	675

Medical Conditions Complicating Pregnancy	676
Surgical Complications During Pregnancy	683
Prevention of Hemolytic Disease of the Newborn (Erythroblastosis Fetalis)	684
Prevention of Preterm (Premature) Labor	684
Lactation	685
Puerperal Mastitis	686

19. Allergic & Immunologic Disorders 687*Jeffrey L. Kishiyama, MD, &
Daniel C. Adelman, MD*

Atopic Disease	687
Allergic Rhinitis	687
Nonallergic Rhinitis	690
Anaphylaxis, Urticaria, & Angioedema	690
Drug & Food Allergy	692
Immune Complex Disease (Serum Sickness)	693
Pseudoallergic Reactions	694
Immunodeficiency Disorders	694
Selective Immunoglobulin A Deficiency	694
Common Variable Immunodeficiency	695
Diseases of Immunoglobulin Overproduction (Gammopathies)	695
Autoimmunity	697
Autoimmune Diseases	698
Tests for Autoantibodies Associated with Autoimmune Disease	698
Immunogenetics & Transplantation	698
Associations between HLA Antigens & Specific Diseases	698
Clinical Transplantation	698

20. Arthritis & Musculoskeletal Disorders 703*David B. Hellmann, MD, MACP, &
John B. Imboden, Jr., MD*

Diagnosis & Evaluation	703
Degenerative & Crystal-Induced Arthritis	703
Pain Syndromes	710
Autoimmune Diseases	720
Vasculitis Syndromes	737
Seronegative Spondyloarthropathies	746
Infectious Arthritis	750
Infections of Bones	753
Other Rheumatic Disorders	756

21. Fluid & Electrolyte Disorders 757*Masafumi Fukagawa, MD, PhD,
Kiyoshi Kurokawa, MD, MACP,
& Maxine A. Papadakis, MD*

Disorders of Sodium Concentration	758
Hyperosmolar Disorders & Osmolar Gaps	764
Disorders of Potassium Concentration	764
Disorders of Calcium Concentration	768
Disorders of Phosphorus Concentration	771
Disorders of Magnesium Concentration	774
Acid-Base Disorders	775
Fluid Management	784

22. Kidney Disease 785*Suzanne Watnick, MD, & Gail Morrison, MD*

Assessment of Renal Disease	785
Acute Renal Failure	788
Chronic Kidney Disease	793
Glomerulonephropathies	801
Nephrotic Disease in Primary Renal Disorders	807
Nephrotic Disease from Systemic Disorders	808
Diseases Demonstrating Nephritic & Nephrotic Components	809
Tubulointerstitial Diseases	811
Cystic Diseases of the Kidney	812
Multisystem Diseases with Variable Kidney Involvement	815

23. Urologic Disorders 816*Marshall L. Stoller, MD,
Christopher J. Kane, MD, FACS,
& Maxwell V. Meng, MD, FACS*

Evaluation of Hematuria	816
Genitourinary Tract Infections	816
Acute Cystitis	816
Acute Pyelonephritis	817
Acute Bacterial Prostatitis	819
Chronic Bacterial Prostatitis	819
Nonbacterial Prostatitis	820
Prostatodynia	821
Acute Epididymitis	821
Urinary Stone Disease	822
Urinary Incontinence	826
Interstitial Cystitis	826
Male Erectile Dysfunction & Sexual Dysfunction	827
Male Infertility	829
Benign Prostatic Hyperplasia	831

24. Nervous System Disorders 837*Michael J. Aminoff, MD, DSc, FRCP*

Headache	837
Facial Pain	841
Epilepsy	842
Dysautonomia	848
Sensory Disturbances	849
Weakness & Paralysis	849
Transient Ischemic Attacks	850
Stroke	852
Intracranial & Spinal Tumors	860
Nonmetastatic Neurologic Complications of Malignant Disease	865
Pseudotumor Cerebri (Benign Intracranial Hypertension)	865
Selected Neurocutaneous Diseases	866
Movement Disorders	867
Dementia	874
Multiple Sclerosis	874
Vitamin E Deficiency	875
Spasticity	875
Myelopathies in AIDS	876

Myelopathy of Human T Cell Leukemia Virus Infection	876
Subacute Combined Degeneration of the Spinal Cord	876
Wernicke's Encephalopathy	876
Stupor & Coma	876
Head Injury	879
Spinal Trauma	880
Syringomyelia	880
Degenerative Motor Neuron Diseases	881
Peripheral Neuropathies	882
Discogenic Neck Pain	889
Brachial & Lumbar Plexus Lesions	891
Disorders of Neuromuscular Transmission	892
Myopathic Disorders	894
Periodic Paralysis Syndrome	896

25. Psychiatric Disorders 897*Stuart J. Eisendrath, MD, &
Jonathan E. Lichtmacher, MD*

Common Psychiatric Disorders	897
Substance Use Disorders (Drug Dependency, Drug Abuse)	935
Delirium, Dementia, & Other Cognitive Disorders (Formerly: Organic Brain Syndrome)	942
Psychiatric Problems Associated with Hospitalization & Illness	945

26. Endocrine Disorders 949*Paul A. Fitzgerald, MD*

Diseases of the Hypothalamus & Pituitary Gland	949
Diseases of the Thyroid Gland	959
The Parathyroids	986
Metabolic Bone Disease	994
Diseases of the Adrenal Cortex	1001
Diseases of the Adrenal Medulla & Paraganglia	1011
Pancreatic & Duodenal Neuroendocrine Tumors	1015
Diseases of the Testes & Male Breast	1016
Amenorrhea & Menopause	1021
Multiple Endocrine Neoplasia	1028
Clinical Use of Corticosteroids	1030

27. Diabetes Mellitus & Hypoglycemia 1032*Umesh Masharani, MB, BS, MRCP(UK)*

Diabetes Mellitus	1032
Diabetic Coma	1062
The Hypoglycemic States	1068

28. Lipid Abnormalities 1074*Robert B. Baron, MD, MS*

Lipoproteins & Atherogenesis	1074
Lipid Fractions & the Risk of Coronary Heart Disease	1074
Therapeutic Effects of Lowering Cholesterol	1075

Secondary Conditions That Affect			
Lipid Metabolism	1076		
Clinical Presentations	1076		
Screening for High Blood Cholesterol	1076		
Treatment of High Low-Density			
Lipoprotein Cholesterol	1079		
High Blood Triglycerides	1083		
29. Nutritional Disorders	1085		
<i>Robert B. Baron, MD, MS</i>			
Protein-Energy Malnutrition	1085		
Obesity	1086		
Eating Disorders	1089		
Disorders of Vitamin Metabolism	1091		
Diet Therapy	1095		
Nutritional Support	1097		
30. Common Problems in Infectious Diseases & Antimicrobial Therapy	1103		
<i>Richard A. Jacobs, MD, PhD, B. Joseph Guglielmo, PharmD, & Peter V. Chin-Hong, MD</i>			
Fever of Unknown Origin	1103		
Infections in the Immunocompromised			
Patient	1105		
Infections of the Central Nervous System	1111		
Animal & Human Bite Wounds	1114		
Sexually Transmitted Diseases	1115		
Infections in Drug Users	1116		
Acute Infectious Diarrhea	1118		
Infectious Diseases in the Returning Traveler	1121		
Traveler's Diarrhea	1122		
Antimicrobial Therapy	1123		
Hypersensitivity Tests & Desensitization	1130		
Immunization Against Infectious Diseases	1134		
Recommended Immunization of Infants, Children, & Adolescents	1134		
Recommended Immunization of Adults	1134		
Recommended Immunization for Travelers	1147		
31. HIV Infection & AIDS	1150		
<i>Andrew R. Zolopa, MD, & Mitchell H. Katz, MD</i>			
Epidemiology	1150		
Etiology	1153		
Pathogenesis	1153		
Pathophysiology	1153		
Clinical Findings	1153		
Differential Diagnosis	1163		
Prevention	1163		
Treatment	1166		
Course & Prognosis	1177		
32. Viral & Rickettsial Infections	1178		
<i>Hoonmo Koo, MD, & Wayne X. Shandera, MD</i>			
Viral Diseases	1178		
Human Herpesviruses	1178		
Major Vaccine-Preventable Viral Infections	1189		
Other Neurotrophic Viruses	1197		
Other Systemic Viral Diseases	1203		
Common Viral Respiratory Infections	1209		
Adenovirus Infections	1214		
Other Exanthematous Viral Infections	1214		
Viruses & Gastroenteritis	1216		
Enteroviruses That Produce Several Syndromes	1216		
Rickettsial Diseases	1218		
Typhus Group	1218		
Spotted Fevers	1222		
Other Rickettsial & Rickettsial-Like Diseases	1223		
Kawasaki Disease	1225		
33. Bacterial & Chlamydial Infections	1227		
<i>Henry F. Chambers, MD</i>			
Infections Caused by Gram-Positive Bacteria	1227		
Infective Endocarditis	1241		
Infections Caused by Gram-Negative Bacteria	1246		
Actinomycosis	1261		
Nocardiosis	1262		
Infections Caused by Mycobacteria	1262		
Infections Caused by Chlamydiae	1265		
34. Spirochetal Infections	1268		
<i>Susan S. Philip, MD, MPH, & Richard A. Jacobs, MD, PhD</i>			
Syphilis	1268		
Non-Sexually Transmitted Treponematoses	1276		
Selected Spirochetal Diseases	1277		
Relapsing Fever	1277		
Rat-Bite Fever (Spirillary Rat-Bite Fever, Sodoku)	1278		
Leptospirosis	1278		
Lyme Disease (Lyme Borreliosis)	1280		
35. Protozoal & Helminthic Infections	1286		
<i>Philip J. Rosenthal, MD, & Robert S. Goldsmith, MD, MPH, DTM&H</i>			
Protozoal Infections	1286		
African Trypanosomiasis (Sleeping Sickness)	1286		
American Trypanosomiasis (Chagas' Disease)	1288		
Leishmaniasis	1289		
Malaria	1291		
Babesiosis	1300		
Toxoplasmosis	1301		
Amebiasis	1304		
Infections with Pathogenic Free-Living Amebas	1306		
Coccidiosis (Cryptosporidiosis, Isosporiasis, Cyclosporiasis) & Microsporidiosis	1307		
Giardiasis	1309		
Other Intestinal Flagellate Infections	1310		
Trichomoniasis	1311		
Helminthic Infections	1311		
Trematode (Fluke) Infections	1311		

Liver, Lung, & Intestinal Flukes	1313	Special Topics in Prevention	1397
Cestode Infections	1314	Staging of Cancer	1397
Intestinal Nematode (Roundworm)		Types of Cancer	1398
Infections	1318	Lung Cancer	1398
Invasive Nematode (Roundworm)		Alimentary Tract Cancers	1404
Infections	1321	Hepatobiliary Cancers	1417
Filariasis	1324	Cancers of the Genitourinary Tract	1422
36. Mycotic Infections	1328	Primary Cancer Treatment	1433
<i>Samuel A. Shelburne, MD, &</i>		Systemic Cancer Therapy	1433
<i>Richard J. Hamill, MD</i>		Toxicity & Dose Modification of	
Candidiasis	1328	Chemotherapeutic Agents	1433
Histoplasmosis	1329	Cancer Complications: Diagnosis &	
Coccidioidomycosis	1330	Management	1449
Pneumocystosis (<i>Pneumocystis jiroveci</i>		Other Complications	1452
Pneumonia)	1332	The Paraneoplastic Syndromes	1454
Cryptococcosis	1334	Alternative & Complementary Therapies	
Aspergillosis	1335	for Cancer	1457
Mucormycosis	1336	40. Clinical Genetic Disorders	1459
Blastomycosis	1336	<i>Reed E. Pyeritz, MD, PhD</i>	
Paracoccidioidomycosis		Acute Intermittent Porphyria	1459
(South American Blastomycosis)	1336	Alkaptonuria	1460
Sporotrichosis	1337	Down Syndrome	1461
<i>Penicillium marneffeii</i> Infections	1337	Fragile X Mental Retardation	1461
Chromoblastomycosis (Chromomycosis)	1337	Gaucher Disease	1462
Mycetoma (Maduromycosis &		Disorders of Homocysteine Metabolism	1463
Actinomycetoma)	1338	Klinefelter Syndrome	1464
Other Opportunistic Mold Infections	1338	Marfan Syndrome	1464
Antifungal Therapy	1338	Hereditary Hemorrhagic Telangiectasia	1465
37. Disorders Due to Physical Agents	1341	41. Complementary &	1467
<i>Brent R.W. Moelleken, MD, FACS</i>		Alternative Medicine	
Cold & Heat	1341	<i>Ellen F. Hughes, MD, PhD, & Kevin Barrows, MD</i>	
Burns	1346	Herbal Medicines	1468
Electric Shock	1350	Dietary Supplements	1474
Ionizing Radiation Reactions	1351	Acupuncture	1478
Drowning	1353	Mind-Body Medicine	1481
Other Disorders Due to Physical Agents	1354	Appendix: Therapeutic Drug Monitoring	1490
38. Poisoning	1358	& Laboratory Reference Ranges	
<i>Kent R. Olson, MD</i>		<i>C. Diana Nicoll, MD, PhD, MPA</i>	
Initial Evaluation: Poisoning or Overdose	1358	Index	1501
The Symptomatic Patient	1358	ONLINE-ONLY CHAPTERS	
Antidotes & Other Treatment	1361	Anti-infective Chemotherapeutic	
Diagnosis of Poisoning	1364	& Antibiotic Agents	
Laboratory Tests	1364	<i>Richard A. Jacobs, MD, PhD, & B. Joseph Guglielmo, PharmD</i>	
Selected Poisonings	1365	Penicillins	
39. Cancer	1387	Cephalosporins	
<i>Hope S. Rugo, MD</i>		Other β -Lactam Drugs	
Incidence & Etiology	1387		
Environmental, Infectious, & Therapeutic			
Carcinogens	1389		
Prevention of Cancer	1390		
Primary Prevention	1390		
Secondary Prevention (Early Detection)	1396		

Erythromycin Group (Macrolides)
 Ketolides
 Tetracycline Group
 Glycylcyclines
 Chloramphenicol
 Aminoglycosides
 Polymyxins
 Antituberculous Drugs
 Alternative Drugs in Tuberculosis Treatment
 Rifamycins
 Sulfonamides & Antifolate Drugs
 Sulfones Used in the Treatment of Leprosy
 Specialized Drugs Used Against Bacteria
 Streptogramins
 Oxazolidinones
 Daptomycin
 Quinolones
 Pentamidine & Atovaquone
 Urinary Antiseptics
 Antifungal Drugs
 Antiviral Chemotherapy

Diagnostic Testing & Medical Decision Making

C. Diana Nicoll, MD, PhD, MPA, & Michael Pignone, MD, MPH

Benefits, Costs, & Risks
 Performance of Diagnostic Tests
 Test Characteristics
 Use of Tests in Diagnosis & Management
 Odds-Likelihood Ratios

Basic Genetics

Reed E. Pyeritz, MD, PhD

Introduction to Medical Genetics
 Genes & Chromosomes
 Mutation

Genes in Individuals
 Genes in Families
 Disorders of Multifactorial Causation
 Chromosomal Aberrations
 The Techniques of Medical Genetics
 Family History & Pedigree Analysis
 Cytogenetics
 Biochemical Genetics
 DNA Analysis
 Prenatal Diagnosis
 Neoplasia: Chromosomal & DNA Analysis

Basic Immunology

Jeffrey L. Kishiyama, MD, & Daniel C. Adelman, MD

Allergic Diseases
 Atopic Disease
 Clinical Immunology
 Cells Involved in Immunity
 Tests for Cellular Immunity
 Immunoglobulin Structure and Function
 Immunogenetics & Transplantation
 Genetic Control of the Immune Response

Information Technology in Patient Care

Russell J. Cucina, MD, MS

The Internet in Clinical Practice
 Electronic Medical Records
 Computerized Provider Order Entry
 Clinical Decision Support Systems
 Online Information Reliability & Quality
 Assessment
 Online Health-Related Forums
 Mobile Computing for Clinicians
 Telemedicine
 Medical Coding & Terminology

disseminated intravascular coagulation. These are distinguished from cardiogenic pulmonary edema by the clinical setting, the history, and the physical examination. Conversely, in most patients with cardiogenic pulmonary edema, an underlying cardiac abnormality can usually be detected clinically or by the ECG, chest radiograph, or echocardiogram.

The chest radiograph reveals signs of pulmonary vascular redistribution, blurriness of vascular outlines, increased interstitial markings, and, characteristically, the butterfly pattern of distribution of alveolar edema. The heart may be enlarged or normal in size depending on whether heart failure was previously present. Assessment of cardiac function by echocardiography is important, since a substantial proportion of patients has normal EFs with elevated atrial pressures due to diastolic dysfunction. In cardiogenic pulmonary edema, the PCWP is invariably elevated, usually over 25 mm Hg. In noncardiogenic pulmonary edema, the wedge pressure may be normal or even low.

▶ Treatment

In full-blown pulmonary edema, the patient should be placed in a sitting position with legs dangling over the side of the bed; this facilitates respiration and reduces venous return. Oxygen is delivered by mask to obtain an arterial P_{O_2} greater than 60 mm Hg. Noninvasive pressure support ventilation may improve oxygenation and prevent severe CO_2 retention while pharmacologic interventions take effect. However, if respiratory distress remains severe, endotracheal intubation and mechanical ventilation may be necessary.

Morphine is highly effective in pulmonary edema and may be helpful in less severe decompensations when the patient is uncomfortable. The initial dosage is 2–8 mg intravenously (subcutaneous administration is effective in milder cases) and may be repeated after 2–4 hours. Morphine increases venous capacitance, lowering LA pressure, and relieves anxiety, which can reduce the efficiency of ventilation. However, morphine may lead to CO_2 retention by reducing the ventilatory drive. It should be avoided in patients with opioid-induced pulmonary edema, who may improve with opioid-antagonists, and in those with neurogenic pulmonary edema.

Intravenous diuretic therapy (furosemide, 40 mg, or bumetanide, 1 mg—or higher doses if the patient has been receiving long-term diuretic therapy) is usually indicated even if the patient has not exhibited prior fluid retention. These agents produce venodilation prior to the onset of diuresis.

Nitrate therapy accelerates clinical improvement by reducing both BP and LV filling pressures. Sublingual nitroglycerin or isosorbide dinitrate, topical nitroglycerin, or intravenous nitrates will ameliorate dyspnea rapidly prior to the onset of diuresis, and these agents are particularly valuable in patients with accompanying hypertension. Intravenous nesiritide (recombinant BNP), when given as a bolus followed by an infusion, improves dyspnea more rapidly than intravenous nitroglycerin, though this may reflect the cautious way in which nitroglycerin is up-titrated by many practitioners. This agent, as well as nitrates, may precipitate hypotension, especially since these agents are used in combination with

multiple drugs that lower BP. In patients with low-output states—particularly when hypotension is present—positive inotropic agents are indicated. These approaches to treatment have been discussed previously.

Bronchospasm may occur in response to pulmonary edema and may itself exacerbate hypoxemia and dyspnea. Treatment with inhaled β -adrenergic agonists or intravenous aminophylline may be helpful, but both may also provoke tachycardia and supraventricular arrhythmias.

In most cases, pulmonary edema responds rapidly to therapy. When the patient has improved, the cause or precipitating factor should be ascertained. In patients without prior heart failure, evaluation should include echocardiography and in many cases cardiac catheterization and coronary angiography. Patients with acute decompensation of chronic heart failure should be treated to achieve a euvolemic state and have their medical regimen optimized. Generally, an oral diuretic and an ACE inhibitor should be initiated, with efficacy and tolerability confirmed prior to discharge. In selected patients, early but careful initiation of β -blockers in low doses should be considered.

Cotter G et al. Pulmonary edema: new insight on pathogenesis and treatment. *Curr Opin Cardiol*. 2001 May;16(3):159–63. [PMID: 11357010]

Fonarow GC. Pharmacologic therapies for acutely decompensated heart failure. *Rev Cardiovasc Med*. 2002;3 Suppl 4:S18–27. [PMID: 12439427]

Gandhi SK et al. The pathogenesis of acute pulmonary edema associated with hypertension. *N Engl J Med*. 2001 Jan 4;344(1):17–22. [PMID: 11136955]

Jain P et al. Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization. *Am Heart J*. 2003 Feb;145(2 Suppl):S3–17. [PMID: 12594447]

Young JB et al. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. *JAMA*. 2002 Mar 27;287(12):1531–40. [PMID: 11911755]

MYOCARDITIS & THE CARDIOMYOPATHIES

INFECTIOUS MYOCARDITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Often follows an upper respiratory infection.
- ▶ May present with chest pain (pleuritic or nonspecific) or signs of heart failure.
- ▶ ECG may show sinus tachycardia, other arrhythmias, nonspecific repolarization changes, and intraventricular conduction abnormalities.
- ▶ Echocardiogram documents cardiomegaly and contractile dysfunction.
- ▶ Myocardial biopsy, though not sensitive, may reveal a characteristic inflammatory pattern.

► General Considerations

Cardiac dysfunction due to primary myocarditis is presumed to be caused by either an acute viral infection or a postviral immune response. Secondary myocarditis is the result of inflammation caused by nonviral pathogens, drugs, chemicals, physical agents, or inflammatory diseases such as systemic lupus erythematosus. The list of infectious causes of myocarditis is extensive and includes viruses with DNA and RNA cores. The coxsackie virus is the predominant agent, but many others have been implicated. Rickettsial myocarditis occurs with scrub typhus, Rocky Mountain spotted fever, and Q fever. Diphtheritic myocarditis is caused by the exotoxin and is often manifested by conduction abnormalities as well as heart failure.

Chagas' disease, caused by the insect-borne protozoan *Trypanosoma cruzi*, is a common form of myocarditis in Central and South America; the major clinical manifestations appear after a latent period of more than a decade. At this stage, patients present with cardiomyopathy, conduction disturbances, and sudden death. Associated gastrointestinal involvement (megaeosophagus and megacolon) is the rule. Toxoplasmosis causes myocarditis that is usually asymptomatic but can lead to heart failure. Among parasitic infections, trichinosis is the most common cause of cardiac involvement. The potential for the HIV virus to cause myocarditis is now well recognized, though the prevalence of this complication is not known and it appears related to the level of viral load and CD4 count. In addition, other infectious causes of myocarditis are more common in patients with AIDS. A complete list of infectious causes of myocarditis is shown in Table 10–11.

Table 10–11. Major causes of infectious myocarditis.

Viral
Adenovirus, arbovirus (dengue fever, yellow fever), arenavirus (Lassa fever), coxsackie virus, cytomegalovirus, echovirus, encephalomyocarditis virus, Epstein–Barr virus, hepatitis B, herpesvirus, HIV-1, influenza virus, mumps virus, poliomyelitis virus, rabies, respiratory syncytial virus, rubella and rubeola virus, vaccinia virus, varicella virus, variola virus
Bacterial
Bruceellosis, clostridia, diphtheria, <i>Francisella</i> (tularemia), gonococcus, <i>Haemophilus</i> , <i>Legionella</i> , meningococcus, <i>Mycobacterium</i> , <i>Mycoplasma</i> , <i>Pneumococcus</i> , psittacosis, <i>Salmonella</i> , <i>Staphylococcus</i> , <i>Streptococcus</i> , Whipple's disease
Fungal
<i>Actinomyces</i> , <i>Aspergillus</i> , <i>Blastomyces</i> , <i>Candida</i> , <i>Cryptococcus</i> , <i>Histoplasma</i> , <i>Nocardia</i> , <i>Sporothrix</i>
Rickettsial
Rocky Mountain spotted fever, Q fever, scrub typhus, typhus
Spirochetal
<i>Borrelia</i> (Lyme disease and relapsing fever), <i>Leptospira</i> , syphilis
Helminthic
<i>Cysticercus</i> , <i>Echinococcus</i> , <i>Schistosoma</i> , <i>Toxocara</i> (visceral larva migrans), <i>Trichinella</i>
Protozoal
<i>Entamoeba</i> , <i>Leishmania</i> , <i>Trypanosoma</i> (Chagas' disease), toxoplasmosis

Modified, with permission, from Pisani B et al. Inflammatory myocardial disease and cardiomyopathies. *Am J Med.* 1997 May;102(5):459–69.

Giant cell myocarditis is a rare idiopathic disorder characterized by giant cell and lymphocyte infiltration of the heart muscle. Patients usually die of ventricular arrhythmias or heart failure but occasionally respond to immunosuppressive therapy or early transplantation.

► Clinical Findings

A. Symptoms and Signs

Patients may present several days to a few weeks after the onset of an acute febrile illness or a respiratory infection or with heart failure without antecedent symptoms. The onset of heart failure may be gradual or may be abrupt and fulminant. Emboli may occur due to the procoagulant effect of cytokines combined with decreased myocardial contractility and blood pooling. Pleural-pericardial chest pain is common. Examination reveals tachycardia, gallop rhythm, and other evidence of heart failure or conduction defect. Many acute infections are subclinical, though they may present later as idiopathic cardiomyopathy or with ventricular arrhythmias. At times, the presentation may mimic an acute myocardial infarction with ST changes, positive cardiac markers, and regional wall motion abnormalities despite normal coronaries. Microaneurysms may also occur and may be associated with serious ventricular arrhythmias. Patients may present in a variety of ways with fulminant, subacute, or chronic myocarditis.

B. ECG and Chest Radiography

Nonspecific ST–T changes and conduction disturbances are common. Ventricular ectopy may be the initial and only clinical finding. Chest radiograph is nonspecific, but cardiomegaly is frequent, though not universal. Evidence for pulmonary venous hypertension is common and frank pulmonary edema may be present.

C. Diagnostic Studies

There is no specific laboratory study that is consistently present, though the white blood cell count is usually elevated and the sedimentation rate may increase. Troponin I levels are elevated in about one-third of patients, but CK-MB is elevated in only 10%. Echocardiography provides the most convenient way of evaluating cardiac function and can exclude many other processes. Gallium-67 scintigraphy may reveal increased cardiac uptake in acute or subacute myocarditis, but it is not very sensitive. MRI with gadolinium enhancement reveals spotty areas of injury throughout the myocardium. Paired serum viral titers and serologic tests for other agents may indicate the cause.

D. Endomyocardial Biopsy

Pathologic examinations may reveal a lymphocytic inflammatory response with necrosis, but the patchy distribution of abnormalities makes this relatively insensitive. By biopsy, the diagnosis of myocarditis has been established by the 1986 “Dallas” criteria. The diagnosis is dependent on describing the severity of an inflammatory infiltrate with necrosis and degeneration of adjacent myocytes. The

type of infiltrate is dependent on the causal agent; usually this is lymphocytic in viral disease, but it may be neutrophilic, eosinophilic, giant cell, granulomatous, or mixed.

▶ Treatment & Prognosis

Patients with fulminant myocarditis may present with acute cardiogenic shock. Their ventricles are usually not dilated, but thickened (possibly due to myoedema). There is a high death rate, but if the patients recover, they are usually left with no residual cardiomyopathy. Patients who present with subacute disease have a dilated cardiomyopathy and generally make an incomplete recovery. Those who present with chronic disease tend to have only mild dilation of the LV and eventually present with a more restrictive cardiomyopathy.

Specific antimicrobial therapy is indicated when an infecting agent is identified. All patients should receive standard heart failure therapy and have arrhythmias suppressed. Exercise should be limited during the recovery phase. Some believe digoxin should be avoided. Immunosuppressive therapy with corticosteroids and intravenous immunoglobulins may improve the outcome when the process is acute (< 6 months) and if the biopsy suggests ongoing inflammation. However, controlled trials have not been positive, so the value of routine myocardial biopsies in patients presenting with an acute myocarditic picture is uncertain; immunosuppressive therapy without histologic confirmation is clearly unwise, and there are few data to support its use. Patients with fulminant myocarditis require aggressive short-term support including an intra-aortic balloon pump or an LV assist device. Ongoing studies are addressing whether patients with giant cell myocarditis may be responsive to immunosuppressive agents, as a special case. Overall, if improvement does not occur, many patients may be eventual candidates for cardiac transplantation.

Barbaro G. Cardiovascular manifestations of HIV infection. *Circulation*. 2002 Sep 10;106(11):1420–5. [PMID: 12221062]

Brady WJ et al. Myocarditis: emergency department recognition and management. *Emerg Med Clin North Am*. 2004 Nov;22(4):865–85. [PMID: 15474774]

Magnani JW et al. Myocarditis: current trends in diagnosis and treatment. *Circulation*. 2006 Feb 14;113(6):876–90. [PMID: 16476862]

DRUG-INDUCED & TOXIC MYOCARDITIS

A variety of medications, illicit drugs, and toxic substances can produce acute or chronic myocardial injury; the clinical presentation varies widely. Doxorubicin and other cytotoxic agents, emetine, and catecholamines (especially with pheochromocytoma) can produce a pathologic picture of inflammation and necrosis together with clinical heart failure and arrhythmias; toxicity of the first two is dose related. The phenothiazines, lithium, chloroquine, disopyramide, antimony-containing compounds, and arsenicals can also cause ECG changes, arrhythmias, or heart failure. Hypersensitivity reactions to sulfonamides, penicillins, and aminosalicic acid as well as other drugs can result in cardiac dysfunction. Radiation can cause an acute inflam-

matory reaction as well as a chronic fibrosis of heart muscle, usually in conjunction with pericarditis.

The incidence of cocaine cardiotoxicity has increased markedly. Cocaine can cause coronary artery spasm, myocardial infarction, arrhythmias, and myocarditis. Because many of these processes are believed to be mediated by cocaine's inhibitory effect on norepinephrine reuptake by sympathetic nerves, β -blockers have been used therapeutically. In documented coronary spasm, calcium channel blockers and nitrates may be effective.

Floyd JD et al. Cardiotoxicity of cancer therapy. *J Clin Oncol*. 2005 Oct 20;23(30):7685–96. [PMID: 16234530]

Gharib MI et al. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. *Eur J Heart Fail*. 2002 Jun;4(3):235–42. [PMID: 12034146]

Yeh ET et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. *Circulation*. 2004 Jun 29;109(25):3122–31. [PMID: 15226229]

DILATED CARDIOMYOPATHY



ESSENTIALS OF DIAGNOSIS

- ▶ Symptoms and signs of heart failure.
- ▶ Examination often reveals cardiomegaly, elevated JVP, S_3 , S_4 , mitral and tricuspid regurgitation, low systemic BP and pulse width, occasionally pulsus alternans.
- ▶ ECG may show low QRS voltage, nonspecific repolarization abnormalities, intraventricular conduction abnormalities.
- ▶ Radiograph shows cardiomegaly.
- ▶ Echocardiogram confirms LV dilation, thinning, and global dysfunction.

▶ General Considerations

The cardiomyopathies are a heterogeneous group of entities affecting the myocardium primarily and not associated with the major causes of cardiac disease, ie, ischemic heart disease, hypertension, pericardial disease, valvular disease, or congenital defects. Recently, two additional entities have been added to the list: a transient cardiomyopathy due to high catecholamine discharge (Tako-Tsubo cardiomyopathy) and an embryologic defect resulting in massive trabeculation in the LV (ventricular noncompaction). Although some have specific causes, many cases are idiopathic. The classification of cardiomyopathies is based on features of presentation and pathophysiology (Table 10–12).

Dilated cardiomyopathies cause about 25% of all cases of CHF. It usually presents with symptoms and signs of CHF (most commonly dyspnea). Occasionally, symptomatic ventricular arrhythmias are the presenting event. LV dilation and systolic dysfunction (EF < 50%) are essential for diagnosis. Dilated cardiomyopathy occurs more often in blacks than whites and in men more than women. A growing number of cardiomyopathies due to genetic

Table 10–12. Classification of the cardiomyopathies.

	Dilated	Hypertrophic	Restrictive
Frequent causes	Idiopathic, alcoholic, major catecholamine discharge, myocarditis, postpartum, doxorubicin, endocrinopathies, genetic diseases	Hereditary syndrome, possibly chronic hypertension	Amyloidosis, post-radiation, post-open heart surgery, diabetes, endomyocardial fibrosis
Symptoms	Left or biventricular congestive heart failure	Dyspnea, chest pain, syncope	Dyspnea, fatigue, right-sided congestive heart failure
Physical examination	Cardiomegaly, S ₃ , elevated jugular venous pressure, rales	Sustained point of maximal impulse, S ₄ , variable systolic murmur, bisferiens carotid pulse	Elevated jugular venous pressure, Kussmaul's sign
Electrocardiogram	ST–T changes, conduction abnormalities, ventricular ectopy	Left ventricular hypertrophy, exaggerated septal Q waves	ST–T changes, conduction abnormalities, low voltage
Chest radiograph	Enlarged heart, pulmonary congestion	Mild cardiomegaly	Mild to moderate cardiomegaly
Echocardiogram, nuclear studies, MRI	Left ventricular dilation and dysfunction	Left ventricular hypertrophy, asymmetric septal hypertrophy, small left ventricular size, normal or supranormal function, systolic anterior mitral motion, diastolic dysfunction	Small or normal left ventricular size, normal or mildly reduced left ventricular function
Cardiac catheterization	Left ventricular dilation and dysfunction, high diastolic pressures, low cardiac output	Small, hypercontractile left ventricle, dynamic outflow gradient, diastolic dysfunction	High diastolic pressure, "square root" sign, normal or mildly reduced left ventricular function

abnormalities are being recognized, and these may represent up to 25–30% of cases. Often no cause can be identified, but chronic alcohol abuse and unrecognized myocarditis are probably frequent causes. Chronic tachycardia may also precipitate a dilated cardiomyopathy. Amyloidosis, sarcoidosis, hemochromatosis, and diabetes may rarely present as dilated cardiomyopathies, as well as the more classic restrictive picture. The RV may be primarily involved in arrhythmogenic RV dysplasia, an unusual cardiomyopathy with displacement of myocardial cells by adipose tissue, or in Uhl's disease, in which there is extreme thinning of the RV walls. Intraventricular thrombus is not uncommon. Histologically, the picture is one of extensive fibrosis unless a specific diagnosis is established. Myocardial biopsy is rarely useful in establishing the diagnosis, though occasionally the underlying cause (eg, sarcoidosis, hemochromatosis) can be discerned.

► Clinical Findings

A. Symptoms and Signs

In most patients, symptoms of heart failure develop gradually. Cardiomyopathy may be recognized because of asymptomatic cardiomegaly or ECG abnormalities, including arrhythmias. The initial presentation may be severe left or biventricular failure. The physical examination reveals rales, an elevated JVP, cardiomegaly, S₃ gallop rhythm, often the murmurs of functional mitral or tricuspid regurgitation, peripheral edema, or ascites. In severe CHF, Cheyne-Stokes breathing, pulsus alternans, pallor, and cyanosis may be present.

B. ECG and Chest Radiography

The major findings are listed in Table 10–12. Sinus tachycardia is common. Other common abnormalities include left bundle branch block and ventricular or atrial arrhythmias. The chest radiograph reveals cardiomegaly, evidence for left and/or right heart failure, and pleural effusions (right > left).

C. Diagnostic Studies

An echocardiogram is indicated to exclude unsuspected valvular or other lesions and confirm the presence of dilated cardiomyopathy and reduced systolic function (as opposed to diastolic heart failure). Mitral Doppler inflow patterns also help in the diagnosis of associated diastolic dysfunction. Color flow Doppler can reveal tricuspid or mitral regurgitation, and continuous Doppler can help define PA pressures. Exercise or pharmacologic stress myocardial perfusion imaging may suggest the possibility of underlying coronary disease. Radionuclide ventriculography provides a noninvasive measure of the EF and both RV and LV wall motion. Cardiac MRI is particularly helpful in infiltrative processes, such as sarcoidosis or hemochromatosis, and is the diagnostic study of choice for RV dysplasia. MRI can also help define an ischemic etiology by noting gadolinium enhancement consistent with myocardial scar. Cardiac catheterization is seldom of specific value unless myocardial ischemia or LV aneurysm is suspected. The serum ferritin is an adequate screening study for hemochromatosis. The erythrocyte sedimentation rate may be low due to liver congestion. The serum level of BNP or pro-BNP can be used to help quantitate the severity of CHF.

▶ Treatment

Standard therapy for heart failure should include ACE inhibitor, β -blockers, diuretics, and an aldosterone antagonist. Digoxin is a second-line drug but remains favored as an adjunct by some clinicians. Calcium channel blockers should generally be avoided. Sodium restriction is helpful, especially in acute cardiomyopathy. When atrial fibrillation is present, heart rate control is important if sinus rhythm cannot be established or maintained. Many patients may now be candidates for cardiac synchronization therapy with biventricular pacing and an implantable defibrillator. Few cases of cardiomyopathy are amenable to specific therapy for the underlying cause. Alcohol use should be discontinued. There is often marked recovery of cardiac function following a period of abstinence in alcoholic cardiomyopathy. Endocrine causes (thyroid dysfunction, acromegaly, and pheochromocytoma) should be treated. Immunosuppressive therapy is not indicated in chronic dilated cardiomyopathy. The management of CHF is outlined in the section on heart failure.

▶ Prognosis

The prognosis of dilated cardiomyopathy without clinical heart failure is variable, with some patients remaining stable, some deteriorating gradually, and others declining rapidly. Once heart failure is manifest, the natural history is similar to that of other causes of heart failure, with an annual mortality around 11–13%. Arterial and pulmonary emboli are more common in dilated cardiomyopathy than in ischemic cardiomyopathy. Suitable candidates may benefit from long-term anticoagulation, and all patients with atrial fibrillation should be so treated. Some patients may be candidates for cardiac transplantation.

Ardehali H et al. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. *Am Heart J*. 2004 May;147(5):919–23. [PMID: 15131552]

Burkett EL et al. Clinical and genetic issues in familial dilated cardiomyopathy. *J Am Coll Cardiol*. 2005 Apr 5;45(7):969–81. [PMID: 15808750]

Felker GM et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. *N Engl J Med*. 2000 Apr 13;342(15):1077–84. [PMID: 10760308]

Maisch B et al. Dilated cardiomyopathies as a cause of congestive heart failure. *Herz*. 2002 Mar;27(2):113–34. [PMID: 12025458]

Sen-Chowdhry S et al. Arrhythmogenic right ventricular cardiomyopathy: clinical presentation, diagnosis, and management. *Am J Med*. 2004 Nov 1;117(9):685–95. [PMID: 15501207]

TAKOTSUBO CARDIOMYOPATHY



ESSENTIALS OF DIAGNOSIS

- ▶ Occurs after an episode that results in major catecholamine discharge.
- ▶ Acute chest pain or shortness of breath.
- ▶ Predominately affects postmenopausal women.

- ▶ Presents as an acute anterior myocardial infarction, but coronaries normal at cardiac catheterization.
- ▶ ECG often with deep anterior T wave inversion.
- ▶ Imaging reveals apical left ventricular ballooning due to anteroapical stunning of the myocardium.

▶ General Considerations

LV apical ballooning can follow a high catecholamine stress. The resulting shape of the LV suggests a rounded ampulla form similar to an octopus pot (takotsubo pot). The acute myocardial injury that occurs is more common in postmenopausal women. It has been described following some stressful event, such as hypoglycemic, lightning strikes, earthquakes, postventricular tachycardia, during alcohol withdrawal, following surgery, during hyperthyroidism, and following emotional stress.

▶ Clinical Findings

A. Symptoms and Signs

The symptoms are similar to any acute coronary syndrome. Typical angina and dyspnea is usually present. Syncope is rare.

B. ECG and Chest Radiography

The ECG reveals ST segment elevation consistent with an acute myocardial infarction. The chest radiograph is either normal or reveals pulmonary congestion.

C. Diagnostic Studies

The echocardiogram reveals LV apical dyskinesia. The urgent cardiac catheterization reveals the LV apical ballooning in association with normal coronaries.

▶ Treatment

Immediate therapy is similar to any acute myocardial infarction. Initiation of long-term therapy depends on whether LV dysfunction persists. Most patients receive aspirin, β -blockers, and ACE-inhibitors until the LV fully recovers.

▶ Prognosis

Prognosis is good unless there is a serious complication (such as mitral regurgitation, ventricular rupture, ventricular tachycardia). Recovery is expected in most cases after a period of weeks to months. At times, the LV function recovers in days.

Valente AM et al. Unusual cardiomyopathies: ventricular non-compaction and takotsubo cardiomyopathy. *Rev Cardiovasc Med*. 2006 Summer;7(3):111–8. [PMID: 17088856]

HYPERTROPHIC CARDIOMYOPATHY



ESSENTIALS OF DIAGNOSIS

- ▶ May present with dyspnea, chest pain, syncope.

- ▶ Though LV outflow gradient is classic, symptoms are primarily related to diastolic dysfunction.
- ▶ Examination shows sustained apical impulse, S_4 , systolic ejection murmur that increases with Valsalva.
- ▶ ECG shows LVH, occasionally septal Q waves in the absence of infarction.
- ▶ Echocardiogram shows septal hypertrophy, which is usually asymmetric, and enhanced contractility. Systolic anterior motion of the anterior mitral valve is present if there is outflow tract obstruction.

▶ General Considerations

Myocardial hypertrophy unrelated to any pressure or volume overload reduces LV systolic stress, increases the EF, and can result in an “empty ventricle” at end-systole. The interventricular septum may be disproportionately involved (asymmetric septal hypertrophy), but in some cases the hypertrophy is localized to mid ventricle or to the apex. The LV outflow tract is often narrowed during systole between the bulging septum and an anteriorly displaced anterior mitral valve leaflet, causing a dynamic obstruction. The obstruction is worsened by factors that increase myocardial contractility (sympathetic stimulation, digoxin, postextrasystolic beat) or that decrease LV filling (Valsalva maneuver, peripheral vasodilators). The amount of obstruction is preload and afterload dependent and can vary from day to day. The consequence of the hypertrophy is elevated diastolic pressures rather than systolic dysfunction. Rarely, systolic dysfunction develops late in the disease. The LV is usually more involved than the RV and the atria are frequently significantly enlarged. It has been increasingly appreciated that hypertrophic obstructive cardiomyopathy (HOCM) is inherited as an autosomal dominant trait with variable penetrance and is caused by mutations of a number of genes, most of which code for myosin heavy chains or proteins regulating calcium handling. The prognosis is related to the specific gene mutation. These patients usually present in early adulthood. Elite athletes may demonstrate considerable hypertrophy that can be confused with HOCM, but generally diastolic dysfunction is not present. The apical variety is particularly common in those of Asian descent. A hypertrophic cardiomyopathy in the elderly (usually in association with hypertension) has also been defined as a distinct entity. Mitral annular calcification is often present.

▶ Clinical Findings

A. Symptoms and Signs

The most frequent symptoms are dyspnea and chest pain (Table 10–12). Syncope is also common and is typically postexertional, when diastolic filling diminishes and outflow obstruction increases. Arrhythmias are an important problem. Atrial fibrillation is a long-term consequence of chronically elevated LA pressures and is a poor prognostic sign. Ventricular arrhythmias are also common, and sudden death may occur, often in athletes after extraordinary exertion.

Features on physical examination are a bisferiens carotid pulse, triple apical impulse (due to the prominent atrial filling wave and early and late systolic impulses), and

a loud S_4 . The JVP may reveal a prominent a wave due to reduced RV compliance. In cases with outflow obstruction, a loud systolic murmur is present along the left sternal border that increases with upright posture or Valsalva's maneuver and decreases with squatting. These maneuvers help differentiate the murmur of HOCM from that of aortic stenosis. Mitral regurgitation is frequently present as well.

B. ECG and Chest Radiography

LVH is nearly universal in symptomatic patients, though entirely normal ECGs are present in up to 25%, usually in those with localized hypertrophy. Exaggerated septal Q waves inferolaterally may suggest myocardial infarction. The chest radiograph is often unimpressive. Unlike aortic stenosis, the ascending aorta is not dilated.

C. Diagnostic Studies

The echocardiogram is diagnostic, revealing asymmetric LVH, systolic anterior motion of the mitral valve, early closing followed by reopening of the aortic valve, a small and hypercontractile LV, and delayed relaxation and filling of the LV during diastole. The septum is usually 1.3–1.5 times the thickness of the posterior wall. Septal motion tends to be reduced. Doppler ultrasound reveals turbulent flow and a dynamic gradient in the LV outflow tract and, commonly, mitral regurgitation. Abnormalities in the diastolic filling pattern are present in 80% of patients. Myocardial perfusion imaging may suggest septal ischemia in the presence of normal coronary arteries. Cardiac MRI confirms the hypertrophy and contrast enhancement frequently reveals evidence for scar at the junction of the RV attachment to the septum. Cardiac catheterization confirms the diagnosis and assesses the presence of CAD. Frequently, coronary arterial bridging (squeezing in systole) occurs, especially of the septal arteries. Alcohol in small doses can be injected into these septal perforators to create a septal infarction that reduces the outflow tract gradient.

▶ Treatment

β -Blockers should be the initial drug in symptomatic individuals, especially when dynamic outflow obstruction is noted on the echocardiogram. The resulting slower heart rates assist with diastolic filling of the stiff LV. Dyspnea, angina, and arrhythmias respond in about 50% of patients. Calcium channel blockers, especially verapamil, have also been effective in symptomatic patients. Their effect is due primarily to improved diastolic function, but their vasodilating actions can also increase outflow obstruction and cause hypotension. Disopyramide (Norpace) is also used because of its negative inotropic effects; it is usually used in addition to the other therapies. Diuretics are frequently necessary due to the high diastolic pressure and PCWP. Patients do best in sinus rhythm, and atrial fibrillation should be aggressively treated with antiarrhythmics. Dual-chamber pacing may prevent the progression of hypertrophy and obstruction. Nonsurgical septal ablation has been performed by injection of alcohol into septal branches of the left coronary artery with good results in small series of patients. Patients with malignant ventricular arrhythmias and unexplained syncope in the

presence of a positive family history for sudden death are probably best managed with an implantable defibrillator. Excision of part of the outflow myocardial septum (myotomy–myectomy) by surgeons experienced with the procedure has been successful in patients with severe symptoms. Some experts advocate mitral valve replacement, as this results in resolution of the gradient as well, and prevents associated mitral regurgitation.

► Prognosis

The natural history of HOCM is highly variable. Several specific mutations are associated with a higher incidence of early malignant arrhythmias and sudden death, and definition of the genetic abnormality provides the best estimate of prognosis. Some patients remain asymptomatic for many years or for life. Sudden death, especially during exercise, may be the initial event. The highest risk patients are those with a family history of sudden death, those with marked hypertrophy, and those that do not increase their systemic blood pressure with exercise. HOCM is the pathologic feature most frequently associated with sudden death in athletes. Pregnancy is generally well tolerated. Endocarditis prophylaxis is indicated. A final stage may be a transition into dilated cardiomyopathy in 5–10% of patients.

Harris KM et al. Prevalence, clinical profile and significance of LV remodeling in the end-stage phase of hypertrophic cardiomyopathy. *Circulation*. 2006 Jul 18;114(3):216–25. [PMID: 16831987]

Ho CY et al. A contemporary approach to hypertrophic cardiomyopathy. *Circulation*. 2006 Jun 20;113(24):e858–62. [PMID: 16785342]

Sherrod MV. Pathophysiology and treatment of hypertrophic cardiomyopathy. *Prog Cardiovasc Dis*. 2006 Sep–Oct;49(2):123–51. [PMID: 17046437]

RESTRICTIVE CARDIOMYOPATHY



ESSENTIALS OF DIAGNOSIS

- Right heart failure tends to dominate over left heart failure.
- Pulmonary hypertension present.
- Amyloidosis is the most common cause.
- Echocardiography is key to diagnosis.
- MRI and cardiac catheterization are helpful. Myocardial biopsy can confirm.

► General Considerations

Restrictive cardiomyopathy is characterized by impaired diastolic filling with preserved contractile function. The diastolic filling pattern in restrictive cardiomyopathy reveals that early diastolic filling is accentuated (rapid E wave on the echocardiogram/Doppler). The LV systolic function may be mildly depressed and the atria are generally enlarged; if present, hypertrophy of the interatrial septum is a helpful additional

finding diagnostically. The condition is relatively uncommon, with the most frequent causes being amyloidosis. In Africa, endomyocardial fibrosis, a specific entity in which there is severe fibrosis of the endocardium, often with eosinophilia (Löfller's syndrome), is seen. Other causes of restrictive cardiomyopathy are infiltrative cardiomyopathies (eg, hemochromatosis, carcinoid syndrome) and connective tissue diseases (eg, scleroderma).

Amyloidosis results from deposition of various proteins within the myocardium. Primary amyloidosis is caused by deposition of immunoglobulin light chains (AL) by monoclonal plasma cells, often as a consequence of multiple myeloma. The heart may be the only organ involved at times. Systemic amyloidosis is due to production of AA light chains. Familial amyloidosis results from production of a carrier protein called transthyretin. Systemic amyloidosis may affect any organ but is particularly associated with significant pulmonary and renal involvement and with a peripheral neuropathy (that often results in orthostatic hypotension).

► Clinical Findings

A. Symptoms and Signs

Restrictive cardiomyopathy must be distinguished from constrictive pericarditis (Table 10–12). The key feature is that ventricular interaction is accentuated with respiration in constrictive pericarditis, and that interaction is absent in restrictive cardiomyopathy. Pulmonary pressure is invariably elevated in restrictive cardiomyopathy and is normal in uncomplicated constrictive pericarditis.

B. Diagnostic Studies

Conduction disturbances are frequently present. Low voltage on the ECG combined with ventricular hypertrophy revealed by echocardiography are suggestive. Cardiac MRI presents a distinctive pattern in amyloidosis and is a useful screening test. The echocardiogram reveals a small thickened LV with bright myocardium, rapid early diastolic filling revealed by Doppler, and biatrial enlargement. Atrial septal thickening may be evident. Rectal, abdominal fat, or gingival biopsies can confirm systemic involvement, but myocardial involvement may still be present if these are negative, and requires biopsy for confirmation. Demonstration of tissue infiltration on biopsy specimens using special stains followed by immunohistochemical studies and genetic testing is essential to define which specific protein is involved.

► Treatment

Unfortunately, little useful therapy is available for either the causative conditions or the restrictive cardiomyopathy itself. Diuretics can help, but excessive diuresis can produce worsening symptoms. As with most patients with severe right heart failure, loop diuretics, thiazides, and aldosterone antagonists are all useful. Digoxin may precipitate arrhythmias and generally should not be used. β -Blockers help slow heart rates and improve filling. Corticosteroids may be helpful in sarcoidosis but relieve conduction abnormalities more often than heart failure. In amyloidosis, the therapeutic strategy depends on the characterization of the type of

amyloid protein and extent of disease and may include chemotherapy, stem cell transplantation, and liver transplantation. Cardiac transplantation is a potential option in patients with primary cardiac amyloidosis.

Ammash NM et al. Clinical profile and outcome of idiopathic restrictive cardiomyopathy. *Circulation*. 2000 May 30;101(21):2490–6. [PMID: 10831523]

Goldstein JA. Cardiac tamponade, constrictive pericarditis, and restrictive cardiomyopathy. *Curr Probl Cardiol*. 2004 Sep;29(9):503–67. [PMID: 15365561]

Shah KB et al. Amyloidosis and the heart: a comprehensive review. *Arch Intern Med*. 2006 Sep 25;166(17):1805–13. [PMID: 17000935]

Yazdani K et al. Differentiating constrictive pericarditis from restrictive cardiomyopathy. *Rev Cardiovasc Med*. 2005 Spring;6(2):61–71. [PMID: 15976729]

ACUTE RHEUMATIC FEVER & RHEUMATIC HEART DISEASE

ESSENTIALS OF DIAGNOSIS

- ▶ Uncommon in the United States (approximately 2 cases/100,000 population); more common (100 cases/100,000 population) in developing countries.
- ▶ Peak incidence ages 5–15 years.
- ▶ Diagnosis based on Jones criteria and confirmation of streptococcal infection.
- ▶ May involve mitral and other valves acutely, rarely leading to heart failure.

General Considerations

Rheumatic fever is a systemic immune process that is a sequela to β -hemolytic streptococcal infection of the pharynx. Pyodermic infections are not associated with rheumatic fever. Signs of rheumatic fever usually commence 2–3 weeks after infection but may appear as early as 1 week or as late as 5 weeks. In recent years, the disease has become quite uncommon in the United States, except in immigrants; however, there have been reports of new outbreaks in several regions of the United States. The peak incidence is between ages 5 and 15 years; rheumatic fever is rare before age 4 years or after age 40 years. Rheumatic carditis and valvulitis may be self-limited or may lead to slowly progressive valvular deformity. The characteristic lesion is a perivascular granulomatous reaction with vasculitis. The mitral valve is attacked in 75–80% of cases, the aortic valve in 30% (but rarely as the sole valve), and the tricuspid and pulmonary valves in under 5% of cases.

Clinical Findings

The diagnostic criteria first described by Jones were updated in 1992. The presence of two major criteria—or one major and two minor criteria—establishes the diagnosis.

A. Major Criteria

1. Carditis—Carditis is most likely to be evident in children and adolescents. Any of the following suggests the presence of carditis: (1) pericarditis; (2) cardiomegaly, detected by physical signs, radiography, or echocardiography; (3) CHF, right- or left-sided—the former perhaps more prominent in children, with painful liver engorgement due to tricuspid regurgitation; and (4) mitral or aortic regurgitation murmurs, indicative of dilation of a valve ring with or without associated valvulitis. The Carey–Coombs short mid-diastolic mitral murmur may be present.

In the absence of any of the above definitive signs, the diagnosis of carditis depends on the following less specific abnormalities: (1) ECG changes, including changing contour of P waves or inversion of T waves; (2) changing quality of heart sounds; and (3) sinus tachycardia, arrhythmia, or ectopic beats.

2. Erythema marginatum and subcutaneous nodules—

Erythema marginatum begins as rapidly enlarging macules that assume the shape of rings or crescents with clear centers. They may be raised, confluent, and either transient or persistent.

Subcutaneous nodules are uncommon except in children. They are small (≤ 2 cm in diameter), firm, and nontender and are attached to fascia or tendon sheaths over bony prominences. They persist for days or weeks, are recurrent, and are indistinguishable from rheumatoid nodules.

3. Sydenham's chorea—Sydenham's chorea—involuntary choreoathetoid movements primarily of the face, tongue, and upper extremities—may be the sole manifestation; only 50% of cases have other overt signs of rheumatic fever. Girls are more frequently affected, and occurrence in adults is rare. This is the least common (3% of cases) but most diagnostic of the manifestations of rheumatic fever.

4. Polyarthritis—This is a migratory polyarthritis that involves the large joints sequentially. In adults, only a single joint may be affected. The arthritis lasts 1–5 weeks and subsides without residual deformity. Prompt response of arthritis to therapeutic doses of salicylates or nonsteroidal agents is characteristic.

B. Minor Criteria

These include fever, polyarthralgias, reversible prolongation of the PR interval, and an elevated erythrocyte sedimentation rate or CRP. Supporting evidence includes positive throat culture or rapid streptococcal antigen test and elevated or rising streptococcal antibody titer.

C. Laboratory Findings

There is nonspecific evidence of inflammatory disease, as shown by a rapid sedimentation rate. High or increasing titers of antistreptococcal antibodies (antistreptolysin O and anti-DNase B) are used to confirm recent infection; 10% of cases lack this serologic evidence.

► Differential Diagnosis

Rheumatic fever may be confused with the following: rheumatoid arthritis, osteomyelitis, endocarditis, chronic meningococemia, systemic lupus erythematosus, Lyme disease, sickle cell anemia, “surgical abdomen,” and many other diseases.

► Complications

CHF occurs in severe cases. In the longer term, the development of rheumatic heart disease is the major problem. Other complications include arrhythmias, pericarditis with effusion, and rheumatic pneumonitis.

► Treatment

A. General Measures

The patient should be kept at strict bed rest until the temperature returns to normal (without the use of anti-pyretic medications) and the sedimentation rate, plus the resting pulse rate, and the ECG have all returned to baseline.

B. Medical Measures

1. Salicylates—The salicylates markedly reduce fever and relieve joint pain and swelling. They have no effect on the natural course of the disease. Adults may require large doses of aspirin, 0.6–0.9 g every 4 hours; children are treated with lower doses.

2. Penicillin—Penicillin (benzathine penicillin, 1.2 million units intramuscularly once, or procaine penicillin, 600,000 units intramuscularly daily for 10 days) is used to eradicate streptococcal infection if present. Erythromycin may be substituted (40 mg/kg/d).

3. Corticosteroids—There is no proof that cardiac damage is prevented or minimized by corticosteroids. A short course of corticosteroids (prednisone, 40–60 mg orally daily, with tapering over 2 weeks) usually causes rapid improvement of the joint symptoms and is indicated when response to salicylates has been inadequate.

► Prevention of Recurrent Rheumatic Fever

The initial episode of rheumatic fever can usually be prevented by early treatment of streptococcal pharyngitis. (See Chapter 33.) Prevention of recurrent episodes is critical. Recurrences of rheumatic fever are most common in patients who have had carditis during their initial episode and in children, 20% of whom will have a second episode within 5 years. Recurrences are uncommon after 5 years following the first episode, and in patients over 25 years of age. Prophylaxis is usually discontinued after these times except in groups with a high risk of streptococcal infection—parents or teachers of young children, nurses, military recruits, etc. Secondary prevention of rheumatic fever depends on whether carditis has occurred. If there is no evidence for carditis, preventive therapy can be stopped at age 21 years. If carditis has occurred but there is no

residual valvular disease, it can be stopped at 10 years after the episode. If carditis has occurred with residual valvular involvement, it should be continued for 10 years after the last episode or until age 40 years if the patient is in a situation in which reexposure would be expected.

A. Penicillin

The preferred method of prophylaxis is with benzathine penicillin G, 1.2 million units intramuscularly every 4 weeks. Oral penicillin (200,000–250,000 units twice daily) is less reliable.

B. Alternatives for Penicillin-Allergic Patients

If the patient is allergic to penicillin, sulfadiazine (or sulfisoxazole), 1 g daily, or erythromycin, 250 mg orally twice daily, may be substituted. The macrolide azithromycin is similarly effective against group A streptococcal infection. If the patient has not had an immediate hypersensitivity (anaphylactic-type) reaction to penicillin, then cephalosporin may also be used.

► Prognosis

Initial episodes of rheumatic fever may last months in children and weeks in adults. The immediate mortality rate is 1–2%. Persistent rheumatic carditis with cardiomegaly, heart failure, and pericarditis implies a poor prognosis; 30% of children thus affected die within 10 years after the initial attack. After 10 years, two-thirds of patients will have detectable valvular abnormalities (usually thickened valves with limited mobility), but significant symptomatic valvular heart disease or persistent cardiomyopathy occurs in less than 10% of patients with a single episode. In developing countries, acute rheumatic fever occurs earlier in life, recurs more frequently, and the evolution to chronic valvular disease is both accelerated and more severe.

► Rheumatic Heart Disease

Chronic rheumatic heart disease results from single or repeated attacks of rheumatic fever that produce rigidity and deformity of valve cusps, fusion of the commissures, or shortening and fusion of the chordae tendineae. Stenosis or insufficiency results, and the two often coexist. The mitral valve alone is affected in 50–60% of cases; combined lesions of the aortic and mitral valves occur in 20%; pure aortic lesions are less common. Tricuspid involvement occurs in about 10% of cases but only in association with mitral or aortic disease and is thought to be more common when recurrent infections have occurred. The pulmonary valve is rarely affected. A history of rheumatic fever is obtainable in only 60% of patients with rheumatic heart disease.

Carapetis JR et al. Acute rheumatic fever. *Lancet*. 2005 Jul 9–15;366(9480):155–68. [PMID: 16005340]

Lee GM et al. Changing epidemiology of acute rheumatic fever in the United States. *Clin Infect Dis*. 2006 Feb 15;42(4):448–50. [PMID: 16421786]

McDonald M et al. Acute rheumatic fever: a chink in the chain that links the heart to the throat? *Lancet Infect Dis*. 2004 Apr; 4(4):240–5. [PMID: 15050943]

DISEASES OF THE PERICARDIUM

ACUTE INFLAMMATORY PERICARDITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Anterior pleuritic chest pain that is worse supine than upright.
- ▶ Pericardial rub.
- ▶ Fever common.
- ▶ Erythrocyte sedimentation rate usually elevated.
- ▶ ECG reveals diffuse ST segment elevation with associated PR depression.

▶ General Considerations

Acute (< 2 weeks) inflammation of the pericardium may be infectious in origin or may be due to systemic diseases (autoimmune syndromes, uremia), neoplasm, radiation, drug toxicity, hemopericardium, postcardiac surgery, or contiguous inflammatory processes in the myocardium or lung. In many of these conditions, the pathologic process involves both the pericardium and the myocardium.

Viral infections (especially infections with coxsackieviruses and echoviruses but also influenza, Epstein–Barr, varicella, hepatitis, mumps, and HIV viruses) are the most common cause of acute pericarditis and probably are responsible for many cases classified as idiopathic. Males—usually under age 50 years—are most commonly affected. The differential diagnosis is primarily with myocardial infarction. **Tuberculous pericarditis** has become rare in developed countries but remains common in other areas. It results from direct lymphatic or hematogenous spread; clinical pulmonary involvement may be absent or minor, although associated pleural effusions are common. **Bacterial pericarditis** has become rare and usually results from direct extension from pulmonary infections. Pneumococci can cause a primary pericardial infection. *Borrelia burgdorferi*, the organism responsible for Lyme disease, can also cause myopericarditis. **Uremic pericarditis** is a common complication of renal failure. The pathogenesis is uncertain; it occurs both with untreated uremia and in otherwise stable dialysis patients. Spread of adjacent lung cancer as well as invasion by breast cancer, renal cell carcinoma, Hodgkin's disease, and lymphomas are the most common **neoplastic processes** involving the pericardium and have become the most frequent causes of pericardial tamponade in many countries. Pericarditis may occur 2–5 days after infarction due to an inflammatory reaction to transmural myocardial necrosis (**postmyocardial infarction or postcardiotomy pericarditis (Dressler's syndrome)**). **Radia-**

tion can initiate a fibrinous and fibrotic process in the pericardium, presenting as subacute pericarditis or constriction. Radiation pericarditis usually follows treatments of more than 4000 cGy delivered to ports including more than 30% of the heart.

Other causes of pericarditis include connective tissue diseases, such as lupus erythematosus and rheumatoid arthritis, drug-induced pericarditis (minoxidil, penicillins), and myxedema.

▶ Clinical Findings

A. Symptoms and Signs

The presentation and course of inflammatory pericarditis depend on its cause, but all syndromes are often (not always) associated with chest pain, which is usually pleuritic and postural (relieved by sitting). The pain is substernal but may radiate to the neck, shoulders, back, or epigastrium. Dyspnea may also be present and the patient is often febrile. A pericardial friction rub is characteristic, with or without evidence of fluid accumulation or constriction (see below). The presentation of **tuberculous pericarditis** tends to be subacute, but nonspecific symptoms (fever, night sweats, fatigue) may be present for days to months. Pericardial involvement develops in 1–8% of patients with pulmonary tuberculosis. Symptoms and signs of **bacterial pericarditis** are similar to those of other types of inflammatory pericarditides, but patients appear toxic and are often critically ill. **Uremic pericarditis** can present with or without symptoms; fever is absent. Often **neoplastic pericarditis** is painless, and the presenting symptoms relate to hemodynamic compromise or the primary disease. **Postmyocardial infarction or postcardiotomy pericarditis (Dressler's syndrome)** usually presents as a recurrence of pain with pleural-pericardial features. A rub is often audible, and repolarization changes on the ECG may be confused with ischemia. Large effusions are uncommon, and spontaneous resolution usually occurs in a few days. Dressler's syndrome occurs weeks to several months after myocardial infarction or open heart surgery, may be recurrent, and probably represents an autoimmune syndrome. Patients present with typical pain, fever, malaise, and leukocytosis. Occasionally, the syndrome will occur within days of surgery. Rarely, other symptoms of an autoimmune disorder, such as joint pain and fever, may occur. Tamponade is rare with Dressler's syndrome after myocardial infarction but not when it occurs postoperatively. The clinical onset of **radiation pericarditis** is usually within the first year but may be delayed for many years.

B. Laboratory Findings and Diagnostic Studies

The diagnosis of **viral pericarditis** is usually clinical, and leukocytosis is often present. Rising viral titers in paired sera may be obtained for confirmation. Cardiac enzymes may be slightly elevated, reflecting a myocarditic component. The echocardiogram is often normal or reveals only a trivial amount of fluid during the acute inflammatory process. The diagnosis of **tuberculous pericarditis** can be inferred if acid-fast bacilli are found elsewhere. The tuberculous pericardial effusions are usually small or moderate but may be large.

The yield of organisms by pericardiocentesis is low; pericardial biopsy has a higher yield but may also be negative, and pericardiectomy may be required. If **bacterial pericarditis** is suspected on clinical grounds, diagnostic pericardiocentesis may be of value. In **uremic patients** not on dialysis, the incidence of pericarditis correlates roughly with the level of blood urea nitrogen (BUN) and creatinine. The pericardium is characteristically “shaggy” in uremic pericarditis, and the effusion is hemorrhagic and exudative. The diagnosis of **neoplastic pericarditis** can occasionally be made by cytologic examination of the effusion or by pericardial biopsy, but it may be difficult to establish clinically if the patient has received mediastinal radiation within the previous year. Neoplastic pericardial effusions develop over a long period of time and may become quite huge (> 2 L). The sedimentation rate is high in **postmyocardial infarction or postcardiotomy pericarditis**. Large pericardial effusions and accompanying pleural effusions are frequent. Myxedema pericardial effusions due to hypothyroidism usually are characterized by the presence of cholesterol crystals.

C. Other Studies

The ECG usually shows generalized ST and T wave changes and may manifest a characteristic progression beginning with diffuse ST elevation, followed by a return to baseline and then to T wave inversion. Atrial injury is often present and manifested by PR depression especially in the limb leads. The chest radiograph is frequently normal, but may show cardiac enlargement if fluid has collected, as well as signs of related pulmonary disease. Mass lesions and enlarged lymph nodes may suggest a neoplastic process. MRI and CT scan can visualize neighboring tumor in neoplastic pericarditis.

▶ Treatment

Treatment of **viral pericarditis** is generally symptomatic. Aspirin (650 mg every 3–4 hours) or other nonsteroidal agents (eg, indomethacin, 100–150 mg daily in divided doses) are usually effective. Corticosteroids may be beneficial in unresponsive cases. In general, symptoms subside in several days to weeks. The major early complication is tamponade, which occurs in less than 5% of patients. There may be recurrences in the first few weeks or months. Rare patients will continue to experience recurrences chronically. These patients may require long-term anti-inflammatory medications, either corticosteroids or colchicine. Rarely, acute pericarditis may lead to constrictive pericarditis, when pericardial resection may be necessary (see below). Standard antituberculous drug therapy is usually successful for **tuberculous pericarditis** (see Chapter 9), but constrictive pericarditis can occur. **Uremic pericarditis** usually resolves with the institution of—or with more aggressive—dialysis. Tamponade is fairly common, and partial pericardiectomy (pericardial window) may be necessary. Whereas anti-inflammatory agents may relieve the pain and fever associated with uremic pericarditis, indomethacin and systemic corticosteroids do not affect its natural history. The prognosis with **neoplastic effusion** is dismal, with only a small minority surviving 1 year. If it is compromising the clinical comfort of the

patient, the effusion is initially drained percutaneously. Early attempts at ballooning the pericardium from a subxiphoid approach have been mostly abandoned in favor of surgical approaches. A pericardial window, either by a subxiphoid approach or via video-assisted thoracic surgery, allows for partial pericardiectomy. Instillation of chemotherapeutic agents or tetracycline may occasionally be used to reduce the recurrence rate. Aspirin or other nonsteroidal anti-inflammatory agents in dosages given for viral pericarditis above for 2–4 weeks are usually effective for the treatment of **postmyocardial infarction or postcardiotomy pericarditis (Dressler’s syndrome)**. In more severe cases, corticosteroids should be given in rapidly tapering doses. Relapses do occur and may require slow withdrawal of anti-inflammatory therapy over several months. Colchicine may be required for months to help prevent recurrences. Symptomatic therapy is the initial approach to **radiation pericarditis**, but recurrent effusions and constriction often require surgery.

Imazio M et al. Management, risk factors, and outcomes in recurrent pericarditis. *Am J Cardiol*. 2005 Sep 1;96(5):736–9. [PMID: 16125506]

Lee PJ et al. Cardiovascular effects of radiation therapy: practical approach to radiation therapy-induced heart disease. *Cardiol Rev*. 2005 Mar–Apr;13(2):80–6. [PMID: 15705258]

Ross AM et al. Acute pericarditis. Evaluation and treatment of infectious and other causes. *Postgrad Med*. 2004 Mar;115(3):67–70, 73–5. [PMID: 15038256]

Talreja DR et al. Constrictive pericarditis in 26 patients with histologically normal pericardial thickness. *Circulation*. 2003 Oct 14;108(15):1852–7. [PMID: 14517161]

Troughton RW et al. Pericarditis. *Lancet*. 2004 Feb 28;363(9410):717–27. [PMID: 15001332]

PERICARDIAL EFFUSION

Pericardial effusion can develop during any of the processes previously discussed. The speed of accumulation determines the physiologic importance of the effusion. Because the pericardium stretches, large effusions (> 1000 mL) that develop slowly may produce no hemodynamic effects. Smaller effusions that appear rapidly can cause tamponade. Tamponade is characterized by elevated intrapericardial pressure (> 15 mm Hg), which restricts venous return and ventricular filling. As a result, the stroke volume and pulse pressure fall, and the heart rate and venous pressure rise. Shock and death may result.

▶ Clinical Findings

A. Symptoms and Signs

Pericardial effusions may be associated with pain if they occur as part of an acute inflammatory process or may be painless, as is often the case with neoplastic or uremic effusion. Dyspnea and cough are common, especially with tamponade. Other symptoms may result from the primary disease.

A pericardial friction rub may be present even with large effusions. In cardiac tamponade, tachycardia, tachypnea, a narrow pulse pressure, and a relatively preserved

systolic pressure are characteristic. Pulsus paradoxus—a greater than 10 mm Hg decline in systolic pressure during inspiration due to further impairment of LV filling—is the classic finding, but it may also occur with obstructive lung disease. Central venous pressure is elevated and there is no evident γ descent in the RA, RV, or LV hemodynamic tracings. Edema or ascites are rarely present; these signs favor a more chronic process.

B. Laboratory Findings

Laboratory tests tend to reflect the underlying processes (see causes of pericarditis above).

C. Diagnostic Studies

Chest radiograph can suggest chronic effusion by an enlarged cardiac silhouette with a globular configuration but may appear normal in acute situations. The ECG often reveals nonspecific T wave changes and low QRS voltage. Electrical alternans is present uncommonly but is pathognomonic. It is due to the heart swinging within the large effusion. Echocardiography is the primary method for demonstrating pericardial effusion and is quite sensitive. If tamponade is present, the high intrapericardial pressure may collapse lower pressure cardiac structures, such as the RA and RV. In tamponade, the normal inspiratory reduction in LV filling is accentuated due to RV/LV interaction and there is a > 25% reduction in maximal mitral inflow velocities. Cardiac CT and MRI also demonstrate pericardial fluid and any associated contiguous lesions. Diagnostic pericardiocentesis or biopsy is often indicated for microbiologic and cytologic studies; a pericardial biopsy may be performed relatively simply through a small subxiphoid incision. Unfortunately, the quality of the pericardial fluid rarely leads to a diagnosis, and any type of fluid (serous, serosanguinous, bloody, etc) can be seen in most diseases.

Treatment

Small effusions can be followed clinically by careful observations of the JVP and by testing for a paradoxical pulse. Serial echocardiograms are indicated if no intervention is immediately contemplated. When tamponade is present, urgent pericardiocentesis is required. Because the pressure-volume relationship in the pericardial fluid is curvilinear and upsloping, removal of a small amount of fluid often produces a dramatic fall in the intrapericardial pressure and immediate hemodynamic benefit; but complete drainage with a catheter is preferable. Continued or repeat drainage may be indicated, especially in malignant effusions. Pericardial windows via video-assisted thoracoscopy have been particularly effective in preventing recurrences.

Additional therapy is determined by the nature of the primary process. Recurrent effusion in neoplastic disease and uremia, in particular, may require partial pericardiectomy as noted earlier.

Burgess LJ et al. Role of biochemical tests in the diagnosis of large pericardial effusions. *Chest*. 2002 Feb;121(2):495–9. [PMID: 11834663]

Rienmuller R et al. CT and MR imaging of pericardial disease. *Radiol Clin North Am*. 2004 May;42(3):587–601. [PMID: 15193931]

Shabetai R. Pericardial effusion: haemodynamic spectrum. *Heart*. 2004 Mar;90(3):255–6. [PMID: 14966038]

Wang ZJ et al. CT and MR imaging of pericardial disease. *RadioGraphics*. 2003 Oct;23 Spec No:S167–80. [PMID: 14557510]

CONSTRUCTIVE PERICARDITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Evidence of right heart failure with an elevated JVP, edema, hepatomegaly, and ascites.
- ▶ No fall or an elevation of the JVP with inspiration (Kussmaul's sign).
- ▶ Echocardiographic evidence for septal bounce and reduced mitral inflow velocities with inspiration.
- ▶ Catheterization evidence for RV-LV interaction, a "square root" sign, equalization of diastolic pressures, and normal pulmonary pressure.

▶ General Considerations

Inflammation can lead to a thickened, fibrotic, adherent pericardium that restricts diastolic filling and produces chronically elevated venous pressures. In the past, tuberculosis was the most common cause of constrictive pericarditis, but the process now more often occurs after radiation therapy, cardiac surgery, or viral pericarditis; histoplasmosis is another uncommon cause.

▶ Clinical Findings

A. Symptoms and Signs

The principal symptoms are slowly progressive dyspnea, fatigue, and weakness. Chronic edema, hepatic congestion, and ascites are usually present. Ascites often seems out of proportion to the degree of peripheral edema. The examination reveals these signs and a characteristically elevated jugular venous pressure with a rapid γ descent. This can be detected at bedside by careful observation of the jugular pulse and noting an apparent increased pulse wave at the end of systole (due to accentuation of the v wave by the rapid γ descent). Kussmaul's sign—a failure of the JVP to fall with inspiration—is also a frequent finding. The apex may actually retract with systole and a pericardial "knock" may be heard in early diastole. Pulsus paradoxus is unusual. Atrial fibrillation is common.

B. Diagnostic Studies

The chest radiograph may show normal heart size or cardiomegaly. Pericardial calcification is best seen on the lateral view and is uncommon. It rarely involves the LV apex, and finding of calcification at the LV apex is more consistent with LV aneurysm. Echocardiography rarely demonstrates a thickened pericardium. A septal "bounce" reflecting the rapid early